The earnings season crunch is upon us once more, and among those reporting next week are Intel Corp. (NASDAQ: INTC) and Johnson & Johnson (NYSE: JNJ).
In its second quarter report in July, Intel reported earnings per share of 22 cents, beating Wall Street's expectation by three cents. In fact, Intel has beat analysts' expectations in the past four quarters, and also has had one-year earnings per share growth of 32 percent, which was better than the S&P 500 and the semiconductor industry average. For the third quarter, analysts surveyed by Thomson Financial expect Intel to report EPS of 30 cents -- profit growth of 35 percent and revenue growth of 10 percent -- which is in line with Intel's updated guidance.
Analysts surveyed by Thomson Financial recommend buying INTC: 15 rate it a strong buy, 16 a buy, and only 7 a hold. The share price is trading near its 52-week high of $26.58, up from a 52-week low of $18.75 in March. The share price closed Friday at $25.55.
For more on what's been going on with Intel, check out BloggingStocks' Intel coverage.
Johnson & Johnson has also beat Wall Street expectations in the past four quarters. Its five-year EPS growth rate of 13.5 percent is better than the pharmaceutical industry average, but not quite up to that of the S&P 500. The second quarter report in July beat analysts' EPS expectations by a nickle, coming in at $1.05, and analysts surveyed by Thomson Financial expect earnings per share of $1.00 this quarter (lower EPS in the second half of the year are not unusual for Johnson & Johnson), about even with the same quarter last year.
The consensus of the 21 analysts surveyed by Thomson Financial is that JNJ is a buy; they split evenly at seven a piece for strong buy, buy, and hold. The share price has risen since reaching a 52-week low of $59.77 in July, and closed Friday at $65.94.
For more Johnson & Johnson-related news, see BloggingStocks' Johnson & Johnson coverage.
Both Intel and Johnson & Johnson report earnings on Tuesday.
Will Rich Ross really have a positive impact on Disney's movie operations?
Consumers sick of recession, may spend extra on holidays
Corrections, seasonality and Santa Claus
Reader Comments (Page 1 of 1)
10-16-2007 @ 4:19PM
Seth said...
Overseas sales really helped J&J, even as domestic drug sales were pretty low. This allowed them to beat expectations, and hopefully domestic sales will be higher by next quarter. Credit J&J management skills for really focusing on overseas sales http://www.newsvisual.com/newsvisual/2007/10/johnson-johnson.html .